CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.

Autor: Hińcza-Nowak K; Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, Poland.; Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland., Kowalik A; Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, Poland.; Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 25-406 Kielce, Poland., Walczyk A; Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.; Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland., Pałyga I; Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.; Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland., Gąsior-Perczak D; Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.; Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland., Płusa A; Surgical Pathology, Holycross Cancer Centre, 25-734 Kielce, Poland., Kopczyński J; Surgical Pathology, Holycross Cancer Centre, 25-734 Kielce, Poland., Chrapek M; Faculty of Natural Sciences, Jan Kochanowski University, 25-406 Kielce, Poland., Góźdź S; Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland.; Clinical Oncology, Holycross Cancer Centre, 25-734 Kielce, Poland., Kowalska A; Endocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, Poland.; Collegium Medicum, Jan Kochanowski University, 25-319 Kielce, Poland.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2023 Jun 12; Vol. 24 (12). Date of Electronic Publication: 2023 Jun 12.
DOI: 10.3390/ijms241210019
Abstrakt: Medullary thyroid cancer (MTC) is a rare malignancy, and the treatment of metastatic MTC is challenging. In previous work, immune profiling (RNA-Seq) of MTC identified CD276 as a potential target for immunotherapy. CD276 expression was 3-fold higher in MTC cells than in normal tissues. Paraffin blocks from patients with MTC were analyzed by immunohistochemistry to confirm the results of RNA-Seq. Serial sections were incubated with anti-CD276 antibody, and scored according to staining intensity and the percentage of immunoreactive cells. The results showed that CD276 expression was higher in MTC tissues than in controls. A lower percentage of immunoreactive cells correlated with the absence of lateral node metastasis, lower levels of calcitonin after surgery, no additional treatments, and remission. There were statistically significant associations of intensity of immunostaining and percentage of CD276 immunoreactive cells with clinical factors and the course of the disease. These results suggest that targeting this immune checkpoint molecule CD276 could be a promising strategy for the treatment of MTC.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje